ID

43963

Description

A Study to Evaluate the Effect of AF-219 on Methacholine Hyper-reactivity in Subjects With Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01993329

Lien

https://clinicaltrials.gov/show/NCT01993329

Mots-clés

Versions (2)
  1. 02/04/2016 02/04/2016 -
  2. 20/09/2021 20/09/2021 -
Téléchargé le

20 septembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Asthma NCT01993329

Anglais

Eligibility Asthma NCT01993329

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01993329
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
non-smokers or former smokers, who stopped smoking 6 months prior to screening. former smokers should not have a smoking history of more than 5 pack years (1 pack of 20 cigarettes per day over 5 years).
Description

Non-smoker | Former smoker | Stopped smoking | smoking cigarettes: ____ pack-years history

Type de données

boolean

Alias
UMLS CUI [1]
C0337672
UMLS CUI [2,1]
C0337671
UMLS CUI [2,2]
C0425310
UMLS CUI [2,3]
C2230126
pre-bronchodilator (after abstaining from short acting β2-agonist for ≥8 hrs) forced expiratory volume (fev1) ≥70 percent of the predicted normal value at the screening visit.
Description

FEV1 | pre bronchodilator | Adrenergic beta-2 Receptor Agonists

Type de données

boolean

Alias
UMLS CUI [1,1]
C0748133
UMLS CUI [1,2]
C2599602
UMLS CUI [2]
C2936789
pre-bronchodilator (after abstaining from short acting β2-agonist for ≥8 hrs) forced expiratory volume (fev1) ≥70% of the predicted normal value or if less than 70% must be within +/- 12 % of screening fev1 prior to randomization.
Description

FEV1 | pre bronchodilator | Adrenergic beta-2 Receptor Agonists | Trial Screening

Type de données

boolean

Alias
UMLS CUI [1,1]
C0748133
UMLS CUI [1,2]
C2599602
UMLS CUI [2]
C2936789
UMLS CUI [3]
C1710477
history or diagnosis of asthma for at least 6 months prior to screening according to the global initiative in asthma guidelines (gina, 2012).
Description

Asthma | Before screening procedure

Type de données

boolean

Alias
UMLS CUI [1]
C0004096
UMLS CUI [2,1]
C0332152
UMLS CUI [2,2]
C0220908
use of short acting β2-agonist therapy only (≤ 8 puffs per day) for at least 4 weeks prior to screening and prior to randomisation.
Description

Adrenergic beta-2 Receptor Agonists | Therapeutic procedure

Type de données

boolean

Alias
UMLS CUI [1,1]
C2936789
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0332152
UMLS CUI [1,4]
C0220908
UMLS CUI [2]
C0034656
positive response to methacholine challenge (pc20 ≤ 8 mg/ml) at screening.
Description

Methacholine challenge | Positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C0430567
UMLS CUI [1,2]
C1446409
positive response to atp challenge (pc20 ≤ 200 µmol/ml) at screening.
Description

Adenosine Triphosphate | Challenge | Positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001480
UMLS CUI [1,2]
C0805586
UMLS CUI [1,3]
C1446409
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
hospitalized or attended the emergency department for an asthma attack in the 12 months prior to screening.
Description

Asthma attack | Hospitalization | Emergency room admission

Type de données

boolean

Alias
UMLS CUI [1]
C0347950
UMLS CUI [2]
C0019993
UMLS CUI [3]
C0583237
exacerbation of asthma or lower respiratory tract infection during the 4 weeks before screening.
Description

Exacerbation of asthma | Lower respiratory tract infection

Type de données

boolean

Alias
UMLS CUI [1]
C0349790
UMLS CUI [2]
C0149725
upper respiratory tract infection during the 4 weeks before screening or prior to randomization requiring treatment with antibiotics.
Description

Treatment required for | Upper Respiratory Infections | Antibiotics

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332121
UMLS CUI [1,2]
C0041912
UMLS CUI [2]
C0003232
inhaled or systemic corticosteroids (oral, intravenous, intramuscular) within 4 weeks prior to screening.
Description

Inhaled steroids | systemic steroids | Adrenal Cortex Hormones | Intravenous steroid injection | Intramuscular steroid therapy

Type de données

boolean

Alias
UMLS CUI [1]
C2065041
UMLS CUI [2]
C2825233
UMLS CUI [3]
C0001617
UMLS CUI [4]
C0563322
UMLS CUI [5]
C0585373
short-acting or long-acting antihistamines within 48hrs or 7 days, respectively, prior to screening.
Description

Antihistamines

Type de données

boolean

Alias
UMLS CUI [1]
C0019590
Retour au début de la page

Similar models

Eligibility Asthma NCT01993329

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01993329
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Non-smoker | Former smoker | Stopped smoking | smoking cigarettes: ____ pack-years history
Item
non-smokers or former smokers, who stopped smoking 6 months prior to screening. former smokers should not have a smoking history of more than 5 pack years (1 pack of 20 cigarettes per day over 5 years).
boolean
C0337672 (UMLS CUI [1])
C0337671 (UMLS CUI [2,1])
C0425310 (UMLS CUI [2,2])
C2230126 (UMLS CUI [2,3])
FEV1 | pre bronchodilator | Adrenergic beta-2 Receptor Agonists
Item
pre-bronchodilator (after abstaining from short acting β2-agonist for ≥8 hrs) forced expiratory volume (fev1) ≥70 percent of the predicted normal value at the screening visit.
boolean
C0748133 (UMLS CUI [1,1])
C2599602 (UMLS CUI [1,2])
C2936789 (UMLS CUI [2])
FEV1 | pre bronchodilator | Adrenergic beta-2 Receptor Agonists | Trial Screening
Item
pre-bronchodilator (after abstaining from short acting β2-agonist for ≥8 hrs) forced expiratory volume (fev1) ≥70% of the predicted normal value or if less than 70% must be within +/- 12 % of screening fev1 prior to randomization.
boolean
C0748133 (UMLS CUI [1,1])
C2599602 (UMLS CUI [1,2])
C2936789 (UMLS CUI [2])
C1710477 (UMLS CUI [3])
Asthma | Before screening procedure
Item
history or diagnosis of asthma for at least 6 months prior to screening according to the global initiative in asthma guidelines (gina, 2012).
boolean
C0004096 (UMLS CUI [1])
C0332152 (UMLS CUI [2,1])
C0220908 (UMLS CUI [2,2])
Adrenergic beta-2 Receptor Agonists | Therapeutic procedure
Item
use of short acting β2-agonist therapy only (≤ 8 puffs per day) for at least 4 weeks prior to screening and prior to randomisation.
boolean
C2936789 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0220908 (UMLS CUI [1,4])
C0034656 (UMLS CUI [2])
Methacholine challenge | Positive
Item
positive response to methacholine challenge (pc20 ≤ 8 mg/ml) at screening.
boolean
C0430567 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
Adenosine Triphosphate | Challenge | Positive
Item
positive response to atp challenge (pc20 ≤ 200 µmol/ml) at screening.
boolean
C0001480 (UMLS CUI [1,1])
C0805586 (UMLS CUI [1,2])
C1446409 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Asthma attack | Hospitalization | Emergency room admission
Item
hospitalized or attended the emergency department for an asthma attack in the 12 months prior to screening.
boolean
C0347950 (UMLS CUI [1])
C0019993 (UMLS CUI [2])
C0583237 (UMLS CUI [3])
Exacerbation of asthma | Lower respiratory tract infection
Item
exacerbation of asthma or lower respiratory tract infection during the 4 weeks before screening.
boolean
C0349790 (UMLS CUI [1])
C0149725 (UMLS CUI [2])
Treatment required for | Upper Respiratory Infections | Antibiotics
Item
upper respiratory tract infection during the 4 weeks before screening or prior to randomization requiring treatment with antibiotics.
boolean
C0332121 (UMLS CUI [1,1])
C0041912 (UMLS CUI [1,2])
C0003232 (UMLS CUI [2])
Inhaled steroids | systemic steroids | Adrenal Cortex Hormones | Intravenous steroid injection | Intramuscular steroid therapy
Item
inhaled or systemic corticosteroids (oral, intravenous, intramuscular) within 4 weeks prior to screening.
boolean
C2065041 (UMLS CUI [1])
C2825233 (UMLS CUI [2])
C0001617 (UMLS CUI [3])
C0563322 (UMLS CUI [4])
C0585373 (UMLS CUI [5])
Antihistamines
Item
short-acting or long-acting antihistamines within 48hrs or 7 days, respectively, prior to screening.
boolean
C0019590 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial